Identification of the ‘NORE’ (N-Oct-3 responsive element), a novel structural motif and composite element
暂无分享,去创建一个
Magali Blaud | Monique Erard | R. Alazard | M. Erard | Christine Vossen | Magali Blaud | Robert Alazard | Shmouel Elbaz | Guillaume Icre | Gérard Joseph | Laurence Nieto | G. Joseph | L. Nieto | G. Icre | Shmouel Elbaz | C. Vossen | Laurence Nieto
[1] K. Yamamoto,et al. Transcription factor interactions: selectors of positive or negative regulation from a single DNA element. , 1990, Science.
[2] Ana Filipa Costa,et al. [Small cell lung cancer--state of the art and future perspectives]. , 2007, Revista portuguesa de pneumologia.
[3] A. Keating,et al. Comprehensive Identification of Human bZIP Interactions with Coiled-Coil Arrays , 2003, Science.
[4] Kanefusa Kato,et al. Aldolase C in neuroendocrine tumors: an immunohistochemical study , 1993, Virchows Archiv. B, Cell pathology including molecular pathology.
[5] A. Spassky,et al. Nuclease activity of 1,10-phenanthroline-copper ion. Conformational analysis and footprinting of the lac operon. , 1985, Biochemistry.
[6] D. Bennett,et al. The POU domain transcription factor Brn-2: elevated expression in malignant melanoma and regulation of melanocyte-specific gene expression. , 1995, Oncogene.
[7] Richard H. Lathrop,et al. DNA sequence and structure: direct and indirect recognition in protein-DNA binding , 2002, ISMB.
[8] Wyeth W. Wasserman,et al. In silico identification of metazoan transcriptional regulatory regions , 2003, Naturwissenschaften.
[9] R. Marais,et al. The Brn-2 Transcription Factor Links Activated BRAF to Melanoma Proliferation , 2004, Molecular and Cellular Biology.
[10] M. Katoh,et al. Human FOX gene family (Review). , 2004, International journal of oncology.
[11] L. Lim,et al. Transcription factors in mouse lung development and function. , 2001, American journal of physiology. Lung cellular and molecular physiology.
[12] P. Privalov,et al. DNA binding and bending by HMG boxes: energetic determinants of specificity. , 2004, Journal of molecular biology.
[13] S. Millevoi,et al. Atypical binding of the neuronal POU protein N-Oct3 to noncanonical DNA targets. Implications for heterodimerization with HNF-3 beta. , 2001, European journal of biochemistry.
[14] C. Gridelli,et al. The role of new targeted therapies in small-cell lung cancer. , 2004, Critical reviews in oncology/hematology.
[15] W. Herr,et al. The POU domain: versatility in transcriptional regulation by a flexible two-in-one DNA-binding domain. , 1995, Genes & development.
[16] G. Chrousos,et al. Corticotropin-releasing hormone production by a small cell carcinoma in a patient with ACTH-dependent Cushing’s syndrome , 1994, Journal of endocrinological investigation.
[17] Jeffrey A Whitsett,et al. Foxa2 is required for transition to air breathing at birth. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[18] Magali Blaud,et al. Characteristic patterns of N Oct-3 binding to a set of neuronal promoters. , 2004, Journal of molecular biology.
[19] D. Sigman,et al. Footprinting DNA-protein complexes in situ following gel retardation assays using 1,10-phenanthroline-copper ion: Escherichia coli RNA polymerase-lac promoter complexes. , 1987, Biochemistry.
[20] H. Hansen,et al. Lung cancer. , 1990, Cancer chemotherapy and biological response modifiers.
[21] D S Latchman,et al. Transcription factors as potential targets for therapeutic drugs. , 2000, Current pharmaceutical biotechnology.
[22] J. Darnell. Transcription factors as targets for cancer therapy , 2002, Nature Reviews Cancer.
[23] R. Palmiter,et al. Identification of a neuron-specific promoter of human aromatic L-amino acid decarboxylase gene. , 1993, Brain research. Molecular brain research.
[24] G Vriend,et al. New POU dimer configuration mediates antagonistic control of an osteopontin preimplantation enhancer by Oct-4 and Sox-2. , 1998, Genes & development.
[25] Steven Hahn,et al. Structure and mechanism of the RNA polymerase II transcription machinery , 2004, Nature Structural &Molecular Biology.
[26] S. Khorasanizadeh,et al. Nuclear-receptor interactions on DNA-response elements. , 2001, Trends in biochemical sciences.
[27] R. Thompson,et al. Rat corticotropin-releasing hormone gene: sequence and tissue-specific expression. , 1987, Molecular endocrinology.
[28] H. Niwa,et al. Identification of Sox-2 regulatory region which is under the control of Oct-3/4-Sox-2 complex. , 2002, Nucleic acids research.
[29] K. Jishage,et al. The POU domain transcription factor Brn-2 is required for the determination of specific neuronal lineages in the hypothalamus of the mouse. , 1995, Genes & development.
[30] T. Eulgem. Eukaryotic transcription factors , 2001, Genome Biology.
[31] Juli D. Klemm,et al. Crystal structure of the Oct-1 POU domain bound to an octamer site: DNA recognition with tethered DNA-binding modules , 1994, Cell.
[32] R. Stahel,et al. Human small cell lung cancer expresses the octamer DNA-binding and nervous system-specific transcription factor N-Oct 3 (brain-2). , 1992, Cancer research.
[33] Anna G. Nazina,et al. Distance preferences in the arrangement of binding motifs and hierarchical levels in organization of transcription regulatory information. , 2003, Nucleic acids research.
[34] M. Rosenfeld,et al. POU domain factors in the neuroendocrine system: lessons from developmental biology provide insights into human disease. , 2001, Endocrine reviews.
[35] H. Hamada,et al. A CNS-specific POU transcription factor, Brn-2, is required for establishing mammalian neural cell lineages , 1993, Neuron.
[36] S. Burley,et al. Co-crystal structure of the HNF-3/fork head DNA-recognition motif resembles histone H5 , 1993, Nature.
[37] G. Sutherland,et al. The brn-2 gene regulates the melanocytic phenotype and tumorigenic potential of human melanoma cells. , 1995, Oncogene.
[38] O. Kohlbacher,et al. From sequence to structure and back again: approaches for predicting protein-DNA binding , 2004, Proteome Science.
[39] K. Kaestner,et al. Foxa2 regulates multiple pathways of insulin secretion. , 2004, The Journal of clinical investigation.
[40] Alexander E. Kel,et al. TRANSCompel®: a database on composite regulatory elements in eukaryotic genes , 2002, Nucleic Acids Res..
[41] M Wilmanns,et al. Differential dimer activities of the transcription factor Oct-1 by DNA-induced interface swapping. , 2001, Molecular cell.
[42] E. D. Hyman. A new method of sequencing DNA. , 1988, Analytical biochemistry.
[43] C. Garvie,et al. Recognition of specific DNA sequences. , 2001, Molecular cell.
[44] Wouter de Laat,et al. Linker length and composition influence the flexibility of Oct‐1 DNA binding , 1997, The EMBO journal.
[45] J. Jameson,et al. Transcriptional Control of Gene Expression , 1998 .
[46] D. Latchman,et al. POU family transcription factors in the nervous system , 1999, Journal of cellular physiology.
[47] Akihiko Okuda,et al. The Gene for the Embryonic Stem Cell Coactivator UTF1 Carries a Regulatory Element Which Selectively Interacts with a Complex Composed of Oct-3/4 and Sox-2 , 1999, Molecular and Cellular Biology.
[48] H. Novotná,et al. Expression of the aromatic L-amino acid decarboxylase mRNA in human tumour cell lines of neuroendocrine and neuroectodermal origin. , 1997, European journal of cancer.
[49] M. Rosenfeld,et al. Allosteric effects of Pit-1 DNA sites on long-term repression in cell type specification. , 2000, Science.
[50] M. Rosenfeld,et al. Structure of Pit-1 POU domain bound to DNA as a dimer: unexpected arrangement and flexibility. , 1997, Genes & development.
[51] E. Turner,et al. Highly Cooperative Homodimerization Is a Conserved Property of Neural POU Proteins* , 1998, The Journal of Biological Chemistry.
[52] S. Levy,et al. Predicting transcription factor synergism. , 2002, Nucleic acids research.
[53] T. Eisen. The control of gene expression in melanocytes and melanomas. , 1996, Melanoma research.
[54] Guillaume Paillard,et al. Analyzing protein-DNA recognition mechanisms. , 2004, Structure.
[55] J. Whitsett,et al. Forkhead box A2 transcription factor is expressed in all types of neuroendocrine lung tumors. , 2004, Human pathology.
[56] A. Spassky,et al. DNA-stacking interactions determine the sequence specificity of the deoxyribonuclease activity of 1,10-phenanthroline-copper ion. , 1996, Journal of molecular biology.
[57] D. Ambrosetti,et al. Synergistic activation of the fibroblast growth factor 4 enhancer by Sox2 and Oct-3 depends on protein-protein interactions facilitated by a specific spatial arrangement of factor binding sites , 1997, Molecular and cellular biology.
[58] R Lavery,et al. The definition of generalized helicoidal parameters and of axis curvature for irregular nucleic acids. , 1988, Journal of biomolecular structure & dynamics.
[59] Matthias Wilmanns,et al. Synergism with the Coactivator OBF-1 (OCA-B, BOB-1) Is Mediated by a Specific POU Dimer Configuration , 2000, Cell.
[60] A. Sommer,et al. Aspects of lung cancer gene expression profiling. , 2004, Current opinion in drug discovery & development.
[61] P. Sawchenko,et al. Development and survival of the endocrine hypothalamus and posterior pituitary gland requires the neuronal POU domain factor Brn-2. , 1995, Genes & development.
[62] S. Selvaraj,et al. Specificity of protein-DNA recognition revealed by structure-based potentials: symmetric/asymmetric and cognate/non-cognate binding. , 2002, Journal of molecular biology.
[63] Eisen Tg. The control of gene expression in melanocytes and melanomas. , 1996 .
[64] Michal Galdzicki,et al. Mammalian overlapping genes: the comparative perspective. , 2004, Genome research.
[65] T. Moody,et al. Corticotropin-releasing factor stimulates cyclic AMP, arachidonic acid release, and growth of lung cancer cells , 1994, Peptides.